BR112012014925A2 - compostos promotores de replicação de células beta e métodos de uso dos mesmos - Google Patents

compostos promotores de replicação de células beta e métodos de uso dos mesmos

Info

Publication number
BR112012014925A2
BR112012014925A2 BR112012014925A BR112012014925A BR112012014925A2 BR 112012014925 A2 BR112012014925 A2 BR 112012014925A2 BR 112012014925 A BR112012014925 A BR 112012014925A BR 112012014925 A BR112012014925 A BR 112012014925A BR 112012014925 A2 BR112012014925 A2 BR 112012014925A2
Authority
BR
Brazil
Prior art keywords
methods
beta cell
cell replication
promoting compounds
replication promoting
Prior art date
Application number
BR112012014925A
Other languages
English (en)
Inventor
Justin P Annes
Douglas A Melton
Lee L Rubin
Gordon Weir
Original Assignee
Joslin Diabetes Center Inc
Harvard College
Brigham & Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joslin Diabetes Center Inc, Harvard College, Brigham & Womens Hospital Inc filed Critical Joslin Diabetes Center Inc
Publication of BR112012014925A2 publication Critical patent/BR112012014925A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/507—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/40—Nucleotides, nucleosides, bases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/65—MicroRNA

Abstract

compostos promotores de replicação de células beta e métodos de uso dos mesmos a invenção fornece um método de estimulação ou aumento da replicação ou crescimento de células <225> por contato de uma célula <225> como um inibidor de adenosina cinase (adk), um inibidor de s-adenosilhomocisteina hidrolase ( sahh) ou um ativador de proteinocinase ativada por amp (ampk).
BR112012014925A 2009-12-18 2010-12-17 compostos promotores de replicação de células beta e métodos de uso dos mesmos BR112012014925A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28800109P 2009-12-18 2009-12-18
PCT/US2010/061075 WO2011075665A2 (en) 2009-12-18 2010-12-17 Beta-cell replication promoting compounds and methods of their use

Publications (1)

Publication Number Publication Date
BR112012014925A2 true BR112012014925A2 (pt) 2017-03-01

Family

ID=44167939

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012014925A BR112012014925A2 (pt) 2009-12-18 2010-12-17 compostos promotores de replicação de células beta e métodos de uso dos mesmos

Country Status (14)

Country Link
US (1) US20130023491A1 (pt)
EP (1) EP2513298A4 (pt)
JP (1) JP2013514781A (pt)
KR (1) KR20120113228A (pt)
CN (1) CN102803474A (pt)
AU (1) AU2010330823A1 (pt)
BR (1) BR112012014925A2 (pt)
CA (1) CA2784596A1 (pt)
EA (1) EA201270661A1 (pt)
IL (1) IL220401A0 (pt)
MX (1) MX2012007026A (pt)
SG (1) SG181703A1 (pt)
WO (1) WO2011075665A2 (pt)
ZA (1) ZA201204521B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103193781B (zh) * 2013-04-01 2015-12-23 济南大学 一种sahn酶蛋白的特异性抑制化合物及其合成方法
JP2016057488A (ja) * 2014-09-10 2016-04-21 株式会社ジャパンディスプレイ 自発光型表示装置
US11278616B2 (en) 2015-08-06 2022-03-22 Nitto Denko Corporation Immunity induction promoting composition, and vaccine pharmaceutical composition
TW202321249A (zh) 2015-08-26 2023-06-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６－６雙環芳香環取代之核苷類似物
TN2018000310A1 (en) 2016-03-10 2020-01-16 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as prmt5 inhibitors
CN115626935A (zh) 2016-10-03 2023-01-20 詹森药业有限公司 用作prmt5抑制剂的单环和双环系统取代的卡巴核苷类似物
JP7225106B2 (ja) 2017-02-27 2023-02-20 ヤンセン ファーマシューティカ エヌ．ベー． Ｐｒｍｔ５阻害剤による治療に応答する癌患者の同定におけるバイオマーカーの使用
WO2018160534A1 (en) 2017-02-28 2018-09-07 Joslin Diabetes Center Protection of beta cells from immune attack
AU2018368790A1 (en) 2017-11-20 2020-06-25 Ichan School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
CN111479817B (zh) 2017-12-08 2023-03-21 詹森药业有限公司 螺双环类似物
AU2019205944A1 (en) 2018-01-05 2020-07-09 Icahn School Of Medicine At Mount Sinai Method of increasing proliferation of pancreatic beta cells, treatment method, and composition
WO2019183245A1 (en) 2018-03-20 2019-09-26 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US20220152072A1 (en) * 2019-04-05 2022-05-19 Prelude Therapeutics, Incorporated Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用ｐｒｍｔ５抑制劑治療癌症之方法
LV15670B (lv) * 2021-03-10 2023-11-20 Latvijas Organiskās Sintēzes Institūts Jauni adenozilmerkaptāna atvasinājumi kā vīrusu m-RNS kapinga metiltransferāžu inhibitori

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547942A (en) * 1994-01-04 1996-08-20 Rapaport; Eliezer Method of treatment of diabetes mellitus by administration of adenosine 5'-t
AU3227000A (en) * 1999-02-10 2000-08-29 Ontogeny, Inc. Methods of inducing insulin positive progenitor cells
ATE462447T1 (de) * 1999-06-23 2010-04-15 Univ Vermont Verfahren und mittels zur manipulierung der expression des uncoupling proteins
US20040170705A1 (en) * 2001-03-08 2004-09-02 Dusan Miljkovic Compositions and methods for non-insulin glucose uptake
US7906491B2 (en) * 2002-06-07 2011-03-15 Univisitair Medisch Centrum Utrecht Compounds for modulating the activity of exchange proteins directly activated by cAMP (Epacs)
US8017634B2 (en) * 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
WO2007075956A2 (en) * 2005-12-21 2007-07-05 The Govt. Of The Usa As Represented By The Secretary Of The Department Of Health & Human Services Methods for producing and using pancreatic endocrine cells
JP5721275B2 (ja) * 2009-04-22 2015-05-20 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエス シーアール， ブイ．ブイ．アイ． 治療的使用のための新規７−デアザプリンヌクレオシド

Also Published As

Publication number Publication date
JP2013514781A (ja) 2013-05-02
MX2012007026A (es) 2013-03-18
US20130023491A1 (en) 2013-01-24
WO2011075665A3 (en) 2011-11-17
WO2011075665A2 (en) 2011-06-23
EP2513298A4 (en) 2013-03-27
EA201270661A1 (ru) 2013-06-28
SG181703A1 (en) 2012-07-30
ZA201204521B (en) 2013-09-25
EP2513298A2 (en) 2012-10-24
CA2784596A1 (en) 2011-06-23
AU2010330823A1 (en) 2012-07-05
CN102803474A (zh) 2012-11-28
KR20120113228A (ko) 2012-10-12
IL220401A0 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
BR112012014925A2 (pt) compostos promotores de replicação de células beta e métodos de uso dos mesmos
BR112012008624A2 (pt) inibidores de tirosina quinase de bruton
CL2010001538A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de las proteinas quinasas; composicion farmaceutica; y su uso para el tratamiento del cancer, o un trastorno proliferativo celular.
CR20120510A (es) Derivados de piperidin-4-il azetidina como inhibidores de jak1
CY1116377T1 (el) Αναστολεις της ανθρωπινης πρωτεϊνικης φωσφατασης της τυροσινης και μεθοδοι χρησης
ECSP11010904A (es) Compuestos de pirrolo[2,3-d]pirimidina
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
WO2010031056A3 (en) Methods and compositions for modulating ire1, src, and abl activity
BR112016009200A8 (pt) uso de um inibidor de btk e um inibidor imune do ponto de verificação
CL2010001483A1 (es) Compuestos derivados de 5-fenil-1h-piridin-2-ona y 6-fenil-2h-piridazin-3-ona, inhibidores de tirosina-quinasa (btk); composicion farmaceutica que comprende a dichos compuestos y su uso para el tratamiento de un estado patologico inflamatorio y/o autoinmune.
BR112013007862A2 (pt) ácidos nucleicos manipulados e métodos de uso dos mesmos.
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
NI201000055A (es) 2&#39; - fluoro - 2&#39; - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
CL2009000316A1 (es) Compuestos derivados de urea de benzomorfanos y sus sales, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de trastornos metabolicos.
GT201200189A (es) Antagonistas de pcsk9
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
CU23978B1 (es) Composiciones para anticuerpos que se dirigen a la proteína de complemento c5
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
ECSP109500A (es) Compuestos y composiciones como inhibidores de proteína quinasa
PA8834001A1 (es) Compuestos y composiciones como inhibidores de cinasa
ATE480615T1 (de) Verfahren zur proliferation von stammzellen
CL2008001682A1 (es) Metodos para el mejoramiento de plantas mediante el uso de informacion directa de secuencias de acidos nucleicos.
CL2008003309A1 (es) Compuestos derivados de citosina (=4-amino-pirimidin-2-ona) sustituida, moduladores de quinasas de punto de control del ciclo celular; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento o la disminucion de la progresion del cancer.
BR112013010484A2 (pt) derivados de coelenterazina e métodos de utilizar os mesmos
CU24052B1 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), y método de producción de los mismos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]